Site-specific delivery of cytokines in cancer

Feinberg, 1988, A phase I trial of intravenously-administered recombinant tumor necrosis factor-α in cancer patients, J. Clin. Oncol., 6, 1328, 10.1200/JCO.1988.6.8.1328 Schiller, 1991, Biological and clinical effects of intravenous tumor necrosis factor-α administered three times weekly, Cancer Res., 51, 1651 Leberthon, 1991, Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin-2 immunoconjugate, Cancer Res., 51, 2694 Wiernik, 1994, Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission, Am. J. Hematol., 47, 41, 10.1002/ajh.2830470109 Gutwald, 1994, Peritumoral injections of interleukin 2 induce tumour regression in metastatic malignant melanoma, Br. J. Dermatol., 130, 541, 10.1111/j.1365-2133.1994.tb03397.x Jain, 1988, Determinants of tumor blood flow: a review, Cancer Res., 48, 2641 Lansdorp, 1986, Cyclic tetramolecular complexes of monoclonal antibodies: a new type of cross-linking reagent, Eur. J. Immunol., 16, 679, 10.1002/eji.1830160615 Weiner, 1995, Bispecific monoclonal antibody therapy of B-cell malignancy, Leuk. Lymphoma, 16, 199, 10.3109/10428199509049758 Vallera, 1994, Immunotoxins: will their clinical promise be fulfilled?, Oncology, 83, 309 Kaminski, 1993, Radioimmunotherapy of B-cell lymphoma with (1–131) anti-B1 (anti-CD20) antibody, New Engl. J. Med., 329, 459, 10.1056/NEJM199308123290703 Press, 1993, Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support, New Engl. J. Med., 329, 1219, 10.1056/NEJM199310213291702 Nakajima, 1994, Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin-2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression, 91, 7889 Gillies, 1991, Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody, Hybridoma, 10, 347, 10.1089/hyb.1991.10.347 Gillies, 1992, Antibody-targeted interleukin-2 stimulates T-cell killing of autologos tumour cells, 89, 1428 Sabzevari, 1994, A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice, 91, 9626 Nicolet, 1995, Expression of a tumor-reactive antibody-interleukin-2 fusion protein, after in vivo particle-mediated gene delivery, Cancer Gene Ther., 2, 161 Renner, 1994, Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells, Science, 264, 833, 10.1126/science.8171337 Miller, 1994, Cytokine-mediated gene herapy for cancer, Ann. Surg. Oncol., 1, 436, 10.1007/BF02303818 Colombo, 1994, Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?, Immunol. Today, 15, 48, 10.1016/0167-5699(94)90131-7 Fearon, 1990, Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response, Cell, 60, 397, 10.1016/0092-8674(90)90591-2 Golumbek, 1991, Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4, Science, 254, 713, 10.1126/science.1948050 Kündig, 1995, Fibroblasts as efficient antigen-presenting cells in lymphoid organs, Science, 268, 1343, 10.1126/science.7761853 Tepper, 1994, Experimental and clinical studies of cytokine gene modified tumor cells, Hum. Gene Ther., 5, 153, 10.1089/hum.1994.5.2-153 Pardoll, 1993, Cancer vaccines, Immunol. Today, 14, 310, 10.1016/0167-5699(93)90051-L 1991 Tahara, 1995, Antitumor effects of interleukin-12 (IL-12): applications for the immunotheraphy and gene therapy of cancer, Gene Ther., 2, 96 Boon, 1993, Teaching the immune system to fight cancer, Sci. Am., 268, 82, 10.1038/scientificamerican0393-82 Miller, 1995, Targeted vectors for gene therapy, FASEB J., 9, 190, 10.1096/fasebj.9.2.7781922 Hwu, 1994, The use of gene-modified tumor-infiltrating lymphocytes for cancer therapy, Ann. NY Acad. Sci., 716, 188, 10.1111/j.1749-6632.1994.tb21712.x Kühr, 1994, Transfer of the tumor necrosis factor α gene into hematopoietic progenitor cells as a model for site-specific cytokine delivery after marrow transplantation, Blood, 84, 2966, 10.1182/blood.V84.9.2966.2966 Miller, 1995, Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection, Mol. Cell. Biol., 10, 4239, 10.1128/MCB.10.8.4239 Hurford, 1995, Gene therapy of metastatic cancer by in vivo retroviral gene targeting, Nat. Genet., 10, 430, 10.1038/ng0895-430 Culver, 1992, In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors, Science, 256, 1550, 10.1126/science.1317968 Connors, 1995, The choice of prodrugs for gene directed enzyme pro-drug therapy of cancer, Gene Ther., 2, 702 Jolly, 1994, Viral vector systems for gene therapy, Cancer Gene Ther., 1, 51 Russell, 1993, Retriviral vectors displaying functional antibody fragments, Nucleic Acids Res., 21, 1081, 10.1093/nar/21.5.1081 Chu, 1994, Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins, Gene Ther., 1, 292 Kasahara, 1994, Tissue-specific targeting of retroviral vectors through ligand-receptor interactions, Science, 266, 1373, 10.1126/science.7973726